Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism (original) (raw)

A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate

Roger Lecomte

PloS one, 2017

View PDFchevron_right

Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo

Traci Parry

Metabolites, 2017

View PDFchevron_right

Sunitinib-induced cardiac hypertrophy and the endothelin axis

Pierre-Louis Tharaux

Theranostics, 2021

View PDFchevron_right

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

Flavia Cassiola

Lancet, 2007

View PDFchevron_right

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Commentary

Nesreen Ismail

Lancet, 2007

View PDFchevron_right

Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase

Jean-bernard Durand

Clinical and Translational Science, 2009

View PDFchevron_right

Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents

Sandra Donnini

Cardio-Oncology, 2016

View PDFchevron_right

Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy

Giulio Agnetti

Cardiovascular Complications in Cancer Therapy, 2018

View PDFchevron_right

Differences in Effects on Myocardium and Mitochondria by Angiogenic Inhibitors Suggest Separate Mechanisms of Cardiotoxicity

Emile Chen

Toxicologic Pathology, 2010

View PDFchevron_right

Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection

Christian Cadeddu

Heart Failure Reviews, 2015

View PDFchevron_right

The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes

Brian Necela

Clinical and translational medicine, 2017

View PDFchevron_right

Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin

Theo Wallimann

Comptes Rendus Biologies, 2006

View PDFchevron_right

Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition

Traci Parry

Journal of the American Heart Association, 2017

View PDFchevron_right

The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats

Alan Knapton

Pharmacology Research & Perspectives, 2014

View PDFchevron_right

Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis

Traci Parry

British journal of pharmacology, 2017

View PDFchevron_right

560 POSTER Inhibition of erbB 1/2 by small molecule tyrosine kinase inhibitors, but not trastuzumab, affects metabolic pathways: implications to cardiac toxicity

Sarah Bacus

Ejc Supplements, 2006

View PDFchevron_right

Cardiac metabolism as a driver and therapeutic target of myocardial infarction

Tuuli Kaambre

Journal of Cellular and Molecular Medicine, 2020

View PDFchevron_right

Metabolic Intersection of Cancer and Cardiovascular Diseases: Opportunities for Cancer Therapy

Kiet Nguyen

The Heterogeneity of Cancer Metabolism, 2021

View PDFchevron_right

Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart

Carlo Gabriele Tocchetti

Cardiovascular Research

View PDFchevron_right

The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients

Heinrich Mächler

Scientific Reports, 2018

View PDFchevron_right

Update on cardiotoxicity of anti-cancer treatments

Gian Rosa

European Journal of Clinical Investigation, 2016

View PDFchevron_right

Cardiac Molecular Remodeling by Anticancer Drugs: Doxorubicin Affects More Metabolism While Mitoxantrone Impacts More Autophagy in Adult CD-1 Male Mice

Margarida Duarte Araújo

Biomolecules

View PDFchevron_right

Systems pharmacological analysis of mitochondrial cardiotoxicity induced by selected tyrosine kinase inhibitors

Sihem Ait-Oudhia

Journal of Pharmacokinetics and Pharmacodynamics, 2018

View PDFchevron_right

Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection

Marco Bruno Morelli

Frontiers in Cardiovascular Medicine

View PDFchevron_right

Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs

Giulio Agnetti

Journal of cardiac failure, 2016

View PDFchevron_right

A Multifaceted Evaluation of Imatinib-induced Cardiotoxicity in the Rat

Thuc Lu

Toxicologic Pathology, 2011

View PDFchevron_right

Cardiac MRI Myocardial Functional and Tissue Characterization Detects Early Cardiac Dysfunction in a Mouse Model of Chemotherapy‐Induced Cardiotoxicity

Nivedita Naresh

NMR in Biomedicine, 2020

View PDFchevron_right

Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment

Diwakar Jain

Annals of Translational Medicine

View PDFchevron_right

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

Jean-bernard Durand

Nature Medicine, 2006

View PDFchevron_right